GLP1_NEW
Liraglutide plus canagliflozin injection
CANALIRA_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.55 (0.24 to 9.52) | 0.50 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.26 (0.00 to 7.60) | 0.76 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.30 (1.01 to 10.24) | 0.32 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.85 (1.01 to 15.00) | 0.18 |